# Valinor

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/valinor

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.valinordiscovery.com
- Total disclosed funding: $13M
- Latest round: Seed (Dec 10, 2025)
- Investors on record: 4

## About

Valinor, based in the US, specializes in providing advanced machine learning solutions that enhance clinical drug development by transforming traditional clinical trial methodologies.Valinor was founded in 2024 in San Francisco, US, focusing on advanced machine learning applications for the pharmaceutical and biotechnology sectors. The company has successfully completed one deal as of December 10, 2025, raising USD 13.00 mn in a Seed funding round led by CRV, Pelion Venture Partners, and Harpoon Ventures, with participation from Amino Collective. This financing supports their mission to improve drug development processes.Valinor specializes in advanced machine learning solutions designed to enhance clinical drug development by transforming traditional clinical trial methodologies. The company’s core product offerings include multi-modal virtual patient models that integrate comprehensive longitudinal data across various multi-omics and clinical assay samples. These models simulate therapeutic efficacy at the patient level, allowing for predictions of treatment outcomes prior to initiating clinical trials. Valinor targets clients in the pharmaceutical and biotechnology sectors engaged in drug development, with a clientele spanning North America, Europe, and Asia.Valinor's revenue model is primarily built around partnerships and B2B transactions within the pharmaceutical and biotech industries. The company engages clients through subscription-based access to their virtual patient simulation platforms, enabling pharmaceutical companies to leverage Valinor's advanced predictive capabilities in their clinical trials. This transactional structure facilitates continuous collaboration and support, enhancing the overall drug development process, though specific pricing plans for these services remain undisclosed.In December 2025, Valinor raised USD 13.00 mn in Seed funding to grow its patient data resources, enhance its machine learning models, and increase staff for clinical trial support. The company plans to introduce new products designed to further optimize clinical trial methodologies. Additionally, Valinor seeks to expand its presence into new markets, particularly in Europe and Asia, by mid-2026, bolstering their global reach in pharmaceutical research.

## Funding rounds

- Seed, Dec 10, 2025, $13M — CRV, Pelion Venture Partners, Harpoon Ventures, Amino Collective

## Investors

- CRV (https://capitalatlas.ai/funds/crv) — Seed
- Pelion Venture Partners (https://capitalatlas.ai/funds/pelion-venture-partners) — Seed
- Harpoon Ventures (https://capitalatlas.ai/funds/harpoon-ventures) — Seed
- Amino Collective (https://capitalatlas.ai/funds/amino-collective) — Seed